Send us Feedback

Thallion Pharmaceuticals (TLN)
Analysis
SUMMARY
BULLS
BEARS
Data
DATA CENTRAL
STOCK CHART
Financials
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Thallion and LFB Report Positive Top-Line Results from the Phase II SHIGATEC Trial at 'VTEC 2012'
Marketwire  May 9  Comment 
MONTREAL, CANADA and LES ULIS, FRANCE -- (Marketwire) -- 05/09/12 -- Thallion Pharmaceuticals Inc. (TSX:TLN) and LFB Biotechnologies announced that, earlier today, positive top-line results from the Phase II SHIGATEC trial evaluating the Company's
Thallion Announces 2011 Year End Results
Marketwire  Feb 22  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 02/22/12 -- Thallion Pharmaceuticals Inc. (TSX:TLN) today announced its operational and financial results for the three-month and twelve-month periods ended November 30, 2011. Fourth Quarter Operational Highlights
Thallion and LFB Complete Patient Enrollment of Phase II SHIGATEC Trial
Marketwire  Jan 9  Comment 
MONTREAL, QUEBEC and LES ULIS, FRANCE -- (Marketwire) -- 01/09/12 -- Thallion Pharmaceuticals Inc. (TSX:TLN) and LFB Biotechnologies announced today that they have completed patient enrollment for the high dose cohort (3 mg/kg) of the Phase II
The Legacy Network Ranks No. 905 on Inc. Magazine's Annual Exclusive List of Fastest Growing Companies
Globe Newswire  Sep 21  Comment 
New York, NY, Sept. 21, 2011 (GLOBE NEWSWIRE) -- Inc. magazine today ranked The Legacy Network (TLN) NO. 905 on its fifth annual Inc. 500|5000, an exclusive ranking of the nation's fastest-growing private companies. The list represents the most
Thallion Comments on European E. Coli Outbreak
Marketwire  Jun 6  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 06/06/11 -- Thallion Pharmaceuticals Inc.'s (TSX: TLN) Chief Executive Officer, Dr. Allan Mandelzys, appeared on Bloomberg and BNN's morning television programs earlier today to discuss the Company's Shigamabs®
Thallion narrows Q4 loss to $1.2 million after reporting revenue of $1.5M
Canadian Business  Feb 25  Comment 
MONTREAL - An improvement on the revenue side and a reduction in research and development expenses help Thallion Pharmaceuticals Inc. (TSX:TLN)
Thallion Announces 2010 Third Quarter Results
Marketwire  Oct 12  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 10/12/10 -- Thallion Pharmaceuticals Inc. (TSX: TLN) today announced its operational and financial results for the three-month and nine-month periods ended August 31, 2010. "We are on track to initiate the Phase II
Thallion Q2 loss narrows to $841,219 from $3M last year; revenue soars to $1M
Canadian Business  Jul 12  Comment 
MONTREAL - Thallion Pharmaceuticals Inc. posted improved results in the second quarter thanks to a greater focus on its anti-toxin drug
Thallion Announces 2010 Second Quarter Results
Marketwire  Jul 12  Comment 
MONTREAL, QUEBEC -- (Marketwire) -- 07/12/10 -- Thallion Pharmaceuticals Inc. (TSX: TLN) today announced its operational and financial results for the three-month and six-month periods ended May 31, 2010. Operational Highlights -- Continued progress
Thallion Pharma pays $2.4 million to end Montreal office lease
Canadian Business  Jun 24  Comment 
MONTREAL - Thallion Pharmaceuticals Inc. (TSX:TLN), a Montreal-based drug developer, says it has struck a deal to pay $2.4 million to end its




more ▼WIKI ANALYSIS
 The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.


 




References

Retrieved from "http://www.wikinvest.com/stock/Thallion_Pharmaceuticals_(TLN)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki